| Metersky, Mark |
NCT05079620: Early Antibiotics After Aspiration in ICU Patients |
|
|
| Terminated | 4 | 5 | US | Ceftriaxone, Amoxicillin clavulanic acid, Augmentin, Cefepime, Vancomycin, Levofloxacin | UConn Health | Aspiration, Aspiration Pneumonia | 04/24 | 04/24 | | |
TOLD, NCT04424901: Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19 |
|
|
| Terminated | 2 | 41 | US | Placebo, Dipyridamole Tablets, Persantine | UConn Health | COVID-19 Pneumonia, Vascular Complications | 03/22 | 04/22 | | |
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection |
|
|
| Completed | 2 | 48 | US | AP-PA02, Placebo | Armata Pharmaceuticals, Inc. | Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection | 07/24 | 08/24 | | |
| Rondon, Juan C |
NCT04971109: Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days |
|
|
| Completed | 3 | 467 | US | TPOXX, tecovirimat, TPOXX Placebo, Placebo | SIGA Technologies, United States Department of Defense | Smallpox | 05/23 | 05/23 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection |
|
|
| Completed | 2 | 48 | US | AP-PA02, Placebo | Armata Pharmaceuticals, Inc. | Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection | 07/24 | 08/24 | | |
NCT05644353: A Bioequivalence Study of Mirikizumab (LY3074828) Solution in Healthy Participants |
|
|
| Completed | 1 | 456 | US | Mirikizumab, LY3074828 | Eli Lilly and Company | Healthy | 05/23 | 05/23 | | |
NCT05711381: Phase 1 PK Study to Assess Safety, PK, Tolerability of HM15912 in Subjects With Renal Impairment and Normal Renal Function |
|
|
| Completed | 1 | 16 | US | HM15912 | Hanmi Pharmaceutical Company Limited | Renal Impairment | 08/23 | 08/23 | | |
NCT05599932: Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment |
|
|
| Completed | 1 | 38 | US | Siremadlin, HDM201 | Novartis Pharmaceuticals | Hepatic Impairment | 09/23 | 09/23 | | |
NCT06388616: Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone |
|
|
| Completed | 1 | 30 | US | Balcinrenone, AZD9977 | AstraZeneca | Hepatic Impairment | 09/24 | 09/24 | | |
NCT06475729: A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants |
|
|
| Active, not recruiting | 1 | 484 | US | Citrate-Free Mirikizumab, LY3074828 | Eli Lilly and Company | Healthy | 12/24 | 12/24 | | |
NCT06592482: A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780 |
|
|
| Recruiting | 1 | 42 | US | AZD0780 | AstraZeneca | Renal Impairment | 01/25 | 01/25 | | |
NCT06719128: A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants |
|
|
| Not yet recruiting | 1 | 48 | US | Olomorasib, LY3537982 | Eli Lilly and Company | Hepatic Insufficiency, Healthy | 08/25 | 08/25 | | |
| Navas, Carla |
NCT05603754: A Study Utilizing Patient-Reported Outcomes to Evaluate the Safety and Efficacy of Lorecivivint (SM04690) for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis (STRIDES) |
|
|
| Completed | 3 | 496 | US | Lorecivivint, SM04690, Placebo, Vehicle | Biosplice Therapeutics, Inc., NBCD A/S | Knee Osteoarthritis | 02/24 | 02/24 | | |
Tailwind, NCT05616221: Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection |
|
|
| Completed | 2 | 48 | US | AP-PA02, Placebo | Armata Pharmaceuticals, Inc. | Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection | 07/24 | 08/24 | | |
